Core Viewpoint - Kanglong Chemical (03759.HK) announced that its independent non-executive director, Zeng Kunhong, has voluntarily resigned from his position on the third board of directors, as well as from the audit committee, remuneration and assessment committee, and nomination committee [1] Summary by Categories - **Company Announcement** - Kanglong Chemical has officially reported the resignation of Zeng Kunhong from multiple positions within the company [1]

Core Viewpoint - The company, Kanglong Chemical (03759), has announced an agreement to acquire 82.54% of Baiaode for approximately RMB 1.346 billion, which will make Baiaode a subsidiary of the company [1][2]. Group 1: Acquisition Details - The acquisition will result in Baiaode being directly held by the company, enhancing its position in the innovative drug research and development sector [2]. - Baiaode specializes in drug discovery services based on complex drug target protein preparation, with a focus on structural biology and advantages in cryo-electron microscopy [2][3]. - The acquisition is expected to strengthen the company's biological science service capabilities and enhance its leadership in the global early biological science service sector [2]. Group 2: Synergies and Capabilities - Baiaode possesses advanced hardware and a research team with extensive experience in protein preparation, which will complement the company's large molecule business segment [3]. - The integration of Baiaode's capabilities in complex protein preparation and structural analysis will enhance the company's early antibody discovery and optimization capabilities [3]. - The acquisition will also allow for the sharing of data between Baiaode and the company, leveraging AI technology for improved drug discovery efficiency [3]. Group 3: Financial Impact - Following the acquisition, Baiaode will be consolidated into the company's financial statements using the cost method, which is expected to positively impact the company's operating performance [4]. - The company anticipates that the acquisition will have a short-term and manageable impact on its finances, with the potential for sustainable bank loans based on Baiaode's profitability and debt repayment capacity [4].

Core Viewpoint - The company, Kanglong Chemical (康龙化成), has announced the acquisition of 82.54% of Baiaode for approximately RMB 1.346 billion, which will enhance its capabilities in drug discovery and development services [1][2]. Group 1: Acquisition Details - The acquisition will result in Baiaode becoming a subsidiary of Kanglong Chemical, directly held at 82.54% [2]. - The total consideration for the acquisition is approximately RMB 1.346 billion [1]. Group 2: Strategic Benefits - Baiaode specializes in innovative drug research and development, focusing on complex drug target protein preparation and structural biology, which aligns with Kanglong Chemical's existing biological science services [2][3]. - The integration of Baiaode's structural biology capabilities with Kanglong Chemical's existing services is expected to strengthen the company's position in the global early-stage biological science service market [2][3]. Group 3: Operational Enhancements - Baiaode has advanced hardware and a skilled research team, particularly in protein preparation, which will enhance Kanglong Chemical's capabilities in early antibody discovery and optimization [3]. - The acquisition will allow for the sharing of data and resources, particularly in AI technology development, improving drug discovery efficiency and service quality [3]. Group 4: Financial Impact - Post-acquisition, Baiaode will be consolidated into Kanglong Chemical's financial statements using the cost method, which is anticipated to have a positive impact on the group's operating performance [4]. - The acquisition is expected to have a short-term and manageable impact on the company's finances, with the potential for sustainable bank loans based on Baiaode's profitability and debt repayment capacity [4].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Pharmaron Beijing Co., Ltd. 康 龍 化 成（ 北 京 ）新 藥 技 術 股 份 有 限 公 司 康龍化成（北京）新藥技術股份有限公司（「本公司」）之董事（「董事」）會（「董事 會」）謹此公告，董事會已決議並審議通過多項事項，其中包括第三屆董事會獨立 非執行董事的擬補選，以及本公司章程（「公司章程」）的擬修訂。 在曾坤鴻先生離任後，其已自願同意繼續履行獨立非執行董事及相關董事會 專門委員會委員職責，直至經本公司股東（「股東」）在本公司即將召開的臨時 股東大會（「臨時股東大會」）審議批准新獨立非執行董事擬補選事項為止。曾 坤鴻先生的離任將自臨時股東大會審議通過新獨立非執行董事擬補選事項之 日起生效。 1 （股份代號：3759） 1. 獨立非執行董事離任及卸任 (1) 獨立非執行董事離任及卸任； (2) 第三屆董事會獨立非執行董事的提名及擬補選；及 董事會謹此公告，曾坤鴻先生已自願 ...

Core Viewpoint - 康龙化成 is acquiring 82.54% of佰翱得 for approximately RMB 1.346 billion, enhancing its capabilities in the biopharmaceutical sector and solidifying its leadership in early-stage biological science services globally [1][2] Group 1: Acquisition Details - 康龙化成 will directly hold 82.54% of佰翱得 after the acquisition, making it a subsidiary of the company [1] - The total consideration for the acquisition is approximately RMB 1.346 billion [1] Group 2: Business Synergies - 佰翱得 specializes in innovative drug research and development, focusing on complex drug target protein preparation and structural biology [1] - The acquisition will combine 佰翱得's structural biology capabilities with 康龙化成's existing biological science services, enhancing service offerings to global clients [1] Group 3: Technological Advancements - 佰翱得 possesses advanced hardware and a skilled research team, leading the industry in complex protein preparation [2] - The integration of 佰翱得's capabilities will strengthen 康龙化成's early antibody discovery and optimization within its large molecule business segment [2] - The acquisition will also enhance data capabilities through AI technology, improving drug discovery service efficiency [2]

前三季度营收约为100.85亿元，同比上升14.38%。净利润约为11.4亿元，同比下降19.76%。 格隆汇10月28日丨康龙化成(03759.HK)公布2025年第三季度报告。营收约为人民币36.44亿元，同比上 升13.44%。净利润约为4.4亿元，同比上升42.52%。基本每股收益为0.2493元。 ...

Core Viewpoint - 康龙化成 reported a revenue of 10.086 billion yuan for the first three quarters of 2025, reflecting a year-on-year increase of 14.38%, while the net profit attributable to shareholders decreased by 19.76% to 1.141 billion yuan, with basic earnings per share at 0.6477 yuan [1] Financial Performance - Revenue for the first three quarters reached 10.086 billion yuan, marking a 14.38% increase year-on-year [1] - Net profit attributable to shareholders was 1.141 billion yuan, representing a decrease of 19.76% compared to the previous year [1] - Basic earnings per share stood at 0.6477 yuan [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致之任何損失承擔任何責任。 本次收購完成後，佰翱得將由本公司直接持有82.54%股份，因此成為本公司的 子公司。 Pharmaron Beijing Co., Ltd. 康 龍 化 成（ 北 京 ）新 藥 技 術 股 份 有 限 公 司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：3759） 收購佰翱得82.54%股份 構成關連交易 於2025年10月28日，本公司與佰翱得股東（包括康君寧元、康君仲元及煜灃投 資）訂立佰翱得協議，據此，本公司同意收購，且佰翱得股東同意出售佰翱得 82.54%的股份，總對價約為人民幣1,346百萬元。 本次收購 佰翱得協議 於2025年10月28日，本公司與佰翱得股東（包括康君寧元、康君仲元及煜灃投資） 訂立佰翱得協議，據此，本公司同意收購，且佰翱得股東同意出售佰翱得82.54% 的股份，總對價約為人民幣1,346百萬元，但須遵守佰翱得協議所載的條款及條 件，其主要條款如下： 根據佰翱得協 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致之任何損失承擔任何責任。 Pharmaron Beijing Co., Ltd. 康 龍 化 成（ 北 京 ）新 藥 技 術 股 份 有 限 公 司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：3759） 2025年第三季度報告 本公告乃由康龍化成（北京）新藥技術股份有限公司（「本公司」，連同其附屬公司 「本集團」）根據香港聯合交易所有限公司證券上市規則（「上市規則」）第13.09條及 第13.10B條以及證券及期貨條例（香港法例第571章）第XIVA部項下的內幕消息條 文（定義見上市規則）而作出。 以下為本公司的2025年第三季度報告。除本報告第四節第三部分按照國際會計準 則理事會頒佈的國際財務報告準則（「國際財務報告準則」）編製或另有註釋外，本 2025年第三季度報告所載之財務數據根據中國企業會計準則編製且未經審計。 1 康龍化成（北京）新藥技術股份有限公司 Pharmaron Beijing Co., Ltd. ...

康龙化成（北京）新药技术股份有限公司 股东会议事规则 中国 北京 2025 年 10 月 康龙化成（北京）新药技术股份有限公司 股东会议事规则 第一章 总则 第一条 为规范公司行为，保证股东会依法行使职权，根据《中华人民共和 国公司法》（"《公司法》"）、《中华人民共和国证券法》（"《证券法》"）、公司 股票上市地证券交易所上市规则(包括但不限于《香港联合交易所有限公司证券 上市规则》（"《上市规则》"）)等有关规定和《康龙化成（北京）新药技术股 份有限公司章程》（"《公司章程》"）的规定，制定本规则。 第二条 公司应当严格按照法律、行政法规、公司股票上市地证券交易所上 市规则、《公司章程》及本规则的相关规定召开股东会，保证股东依法行使权利。 公司董事会应当切实履行职责，认真、按时组织股东会。公司全体董事应当 勤勉尽责，确保股东会正常召开和依法行使职权。 第三条 股东会应当在《公司法》等法律、行政法规、部门规章及公司股票 上市地上市规则和《公司章程》规定的范围内行使职权。 第四条 股东会分为年度股东会和临时股东会。年度股东会每年召开一次， 应当于上一会计年度结束后的 6 个月内举行。 公司在上述期限内不能召开 ...